Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. | Ownership

Companies that own Karyopharm Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Wellington Management Co. LLP
8,266,641
13.65%
1,458,258
0.03%
06/30/2018
Consonance Capital Management LP
4,767,078
7.87%
4,767,078
5.36%
06/30/2018
Palo Alto Investors LP
4,663,324
7.7%
983,346
3.78%
06/30/2018
BlackRock Fund Advisors
3,753,838
6.2%
1,178,783
0%
06/30/2018
Ridgeback Capital Management LP
2,732,125
4.51%
2,732,125
79.01%
01/26/2018
The Vanguard Group, Inc.
2,399,606
3.96%
507,589
0%
06/30/2018
SSgA Funds Management, Inc.
2,337,707
3.86%
1,348,776
0%
06/30/2018
Franklin Advisers, Inc.
2,082,756
3.44%
51,272
0.03%
06/30/2018
Fidelity Management & Research Co.
1,540,183
2.54%
-1,492,209
0%
06/30/2018
Point72 Asset Management LP
1,442,183
2.38%
-516,344
0.15%
06/30/2018

About Karyopharm Therapeutics

View Profile
Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.